Trial Profile
A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus High Dose Clopidogrel in Subjects With Type 2 Diabetes Mellitus and Coronary Artery Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Clopidogrel
- Indications Coronary artery disease; Embolism and thrombosis; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms OPTIMUS-3
- 30 Aug 2010 Results have been presented at ESC Congress 2010: Annual Congress of the European Society of Cardiology.
- 16 Nov 2009 Results presented at the 82nd Annual Scientific Sessions of the American Heart Association (AHA).
- 16 Nov 2009 Primary endpoint 'Platelet aggregation' has been met.